Federal grand jury indicts U.S. soldier on terrorism charges
HONOLULU — A federal grand jury in Hawaii indicted a U.S. soldier Friday for attempting to provide material support to the Islamic State group.
Army Sgt. 1st Class Ikaika Kang was arrested by an FBI SWAT team on July 8. Kang was ordered held without bail.
Kang will be arraigned in federal court on Monday when he had previously been scheduled for a preliminary hearing. Kang’s court-appointed attorney, Birney Bervar, told The Associated Press Friday that the indictment was expected.
“We haven’t had a preliminary in federal court here in probably 25 years,” Bervar said. “They don’t like to let us question their witnesses.”
Bervar said his client will plead not guilty on Monday when a federal judge will set a trial date.
Bervar said he is working on getting Kang a mental health evaluation and that his client may suffer from service-related mental health issues.
A “turning point” for Kang’s mental state seems to be a 2011 deployment, Bervar said. “He’s a decorated American soldier for 10 years, goes to Afghanistan and comes back and things start going off the rails.”
Elliot Enoki, Acting U.S. Attorney for the District of Hawaii, and Dana Boente, Acting Assistant Attorney General for National Security, announced that the indictment in a statement.
Kang is charged with four counts of attempting to provide material support to the Islamic State group based on events that occurred in Hawaii between June 21 and July 8, they said.
Federal officials say Kang met with undercover FBI agents he thought were with the terror group and provided classified military documents to the agents.
The FBI said in their criminal complaint that Kang wanted to commit a mass shooting after pledging allegiance to the Islamic State group.
CHICAGO — Cancer patients’ gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.
Chemotherapy is notorious for making hair fall out, but the 14 patients involved were all being treated with new immunotherapy drugs that work differently and have different side effects. A Spanish study suggests that may include restoring hair pigment, at least in patients with lung cancer.
With the first patient, “we thought it could be an isolated case,” said Dr. Noelia Rivera, a dermatologist at Autonomous University of Barcelona.
But she said the research team found the same thing when they asked other patients for photos from before treatment.
The 14 cases were among 52 lung cancer patients being followed to see whether they developed bad side effects from the drugs — Keytruda, Opdivo and Tecentriq.
While most patients did not have a color change, the 14 cases suggest it’s not an isolated finding. In 13 patients, hair turned darkish brown or black. In one patient, it turned black in patches.
In another odd twist, the same drugs have been linked previously with hair losing color in patients with another cancer, melanoma.
All but one of the 14 patients in the Spanish study had at least stable disease and responded better to treatment than other patients, suggesting that hair darkening might be an indication that the drugs are working, the researchers said.
Rivera said they are continuing the study to search for an explanation and to see if the cases are just a fluke.
“It’s a fascinating report — one of those things that comes out of the blue,” said Dr. June Robinson, a Northwestern University research professor in dermatology. Robinson is also editor of the medical journal JAMA Dermatology, which published the study online this month.
She said the results deserve a deeper look but cautioned that it’s way too soon to suggest that they might lead to new treatments for gray hair.
Rivera noted that the study drugs have serious side effects that make them unsafe for healthy people. But if it’s confirmed that they do change hair color, a different drug could be developed to treat gray hair, she said.
The pharmaceutical industry has previously capitalized on unexpected drug side effects; examples include the male pattern baldness drug Propecia, the eyelash growing drug Latisse, and Botox anti-wrinkle injections. Active ingredients in these drugs were initially approved to treat enlarged prostates, eye pressure problems, and eye muscle spasms.